21st Annual New England Critical Care Pharmacotherapy Symposium, September 27, 2024

Norwood, MA US
September 27, 2024

Four Points Sheraton Norwood Hotel - Norwood, MA - September 27, 2024

Claiming Credit

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete evaluation and claim your credit on the following page.

 

Target Audience

This inter-professional continuing education activity is developed for hospital pharmacists, critical care pharmacists and drug policy decision makers and other health care providers.

Learning Objectives

  • Apply Evidence-based knowledge to the care of critically ill patients.
  • Analyze and employ published evidence (including practice guidelines) surrounding medication therapy in the ICU
  • Design and evaluate a pharmacotherapeutic regimen for ICU patients.
Course summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 5.00 Participation
Course opens: 
09/27/2024
Course expires: 
10/28/2024
Event starts: 
09/27/2024 - 8:00am EDT
Event ends: 
09/27/2024 - 4:30pm EDT
Add to calendar: 
Rating: 
0
Four Points Sheraton Norwood Hotel
1125 Boston-Providence Turnpike
Norwood, MA 02062
United States

Boston University Chobanian & Avedisian School of Medicine Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

Speakers Disclosures
Drs. Bittner, Culshaw, Feeney, Kane-Gil, Rochwerg, Smith and Szumita, have no relevant financial relationships to disclose.

Off-Label Discussion: The faculty members do not plan on discussing the unlabeled/investigational use of any commercial products. 

Planning Committee and Disclosures
Dr. Devlin, program course director and speaker, is a consultant for Mallinckrodt,Ceribell and Noven Pharma. He also receives research funding from Sedana Medical, and BioExcel Therapeutics. 

Dr. Degrado is a consultant for Marinus Pharmaceuticals.

Dr. Roberts is a consultant for Wolters Kluwer.

Dr. Szumita is a speaker for Trevena Inc.

Dr. Weinhouse has no relevant financial relationships to disclose.

Accreditor Disclosures
Dr. Zakeri, Northeastern University’s Director of Professional Programs, Office of Continuing Pharmacy Education, has no relevant financial relationships to disclose.

The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education have no relevant financial relationships to disclose: Dr. Daniel Alford, Boston University’s CME Course Director and Assistant Dean and Michael Burk, BS, Operations Manager.



Joint Accreditation
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.




Physicians
The Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Available Credit

  • 5.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 5.00 Participation

Astellas, Ferring Pharmaceuticals, Fresenisu Kabi, Innovivia, Intelliguard, Mallinckrodt Pharmaceuticals, and Shinogi. 

Please login or register to take this course.

Please click on "Take Course" above to begin the credit claiming process. 

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS.  ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE.  TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.  IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS.  IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.